|
|
|
Commercial Strategy
Adamas plans to develop its CNS product candidates through NDA approval and to retain US commercial rights to
products that can be sold through a small CNS sales force, beginning with ADS-5102. Adamas is
interested in working with partners with complementary marketing, sales and distribution capabilities for other
marketing channels within the U.S. as well as in other world markets.
ADS-5102 (amantadine HCl ER)
Adamas plans to develop ADS-5102 through NDA and to retain US commercial rights. Adamas is interested in working with
partners with complementary marketing, sales and distribution capabilities for ADS-5102 outside of the US.
MDX-8704 (memantine HCl ER/donepezil HCl, US market)
Adamas and Forest Laboratories, Inc. have entered into an agreement for the development and commercialization of a
fixed-dosed combination (FDC) of memantine HCl extended release and donepezil HCl as a once daily therapy for the
treatment of moderate to severe dementia of the Alzheimer’s type in the United States. Under the agreement, Forest
and Adamas will collaborate on the development of the memantine HCl extended release and donepezil HCl FDC and Forest
will have exclusive US commercialization rights.
ADS-8704 (memantine HCl ER/donepezil HCl, ex-US market)
Adamas retained the development, manufacturing and commercialization rights for ADS-8704 outside of the United States
and is interested in working with partners with complementary regulatory, marketing, sales and distribution capabilities.
Click here to contact Adamas Business Development.
|